Patents by Inventor Ari-Angel PORGADOR

Ari-Angel PORGADOR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins with extended serum half life
    Patent number: 11911443
    Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: February 27, 2024
    Assignees: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
    Inventors: Ari-Angel Porgador, David Ben-Menahem, Roee Atlas
  • Anti-PCNA monoclonal antibodies and use thereof
    Patent number: 11667700
    Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: June 6, 2023
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventor: Ari-Angel Porgador
  • FUSION PROTEINS WITH EXTENDED SERUM HALF LIFE
    Publication number: 20220023388
    Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Inventors: Ari-Angel PORGADOR, David BEN-MENAHEM, Roee ATLAS
  • Fusion proteins with extended serum half life
    Patent number: 11141463
    Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 12, 2021
    Assignees: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
    Inventors: Ari-Angel Porgador, David Ben-Menahem, Roee Atlas
  • ANTI-PCNA MONOCLONAL ANTIBODIES AND USE THEREOF
    Publication number: 20210032320
    Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Inventor: Ari-Angel PORGADOR
  • Anti-PCNA monoclonal antibodies and use thereof
    Patent number: 10836818
    Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 17, 2020
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY I
    Inventor: Ari-Angel Porgador
  • ANTI-PCNA MONOCLONAL ANTIBODIES AND USE THEREOF
    Publication number: 20200031910
    Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
    Type: Application
    Filed: December 14, 2017
    Publication date: January 30, 2020
    Inventor: Ari-Angel PORGADOR
  • FUSION PROTEINS WITH EXTENDED SERUM HALF LIFE
    Publication number: 20190255150
    Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 22, 2019
    Inventors: Ari-Angel PORGADOR, David BEN-MENAHEM, Roee ATLAS